Phase 2 Results of Rigel's R788 Show Clinical Benefit in Diffuse Large B-Cell Lymphoma and CLL

[Guest guest]

Phase 2 Results of Rigel's R788 Show Clinical Benefit in Diffuse Large B-Cell

Lymphoma and CLL

Results To Be Presented Today at ASH Meeting in San Francisco

Last update: 2:00 p.m. EST Dec. 7, 2008

SAN FRANCISCO, Dec 07, 2008 /PRNewswire-FirstCall via COMTEX/ -- Results of the

Phase 2 clinical trial of R788 (fostamatinib disodium) in patients with relapsed

or refractory B-Cell non-Hodgkin's lymphoma (NHL) will be presented today at a

plenary session during the 50th Annual American Society of Hematology (ASH)

Meeting. The results affirm preliminary reports that Rigel's oral Syk inhibitor

is well-tolerated by these patients and shows therapeutic benefit in patients

suffering from diffuse large B-Cell lymphoma (DLBCL) and chronic lymphocytic

leukemia/small lymphocytic lymphoma (CLL/SLL).

Rigel will host a conference call today at 4:00 p.m. PST to discuss these

results (see conference call details below).

" Despite the fact that the patients enrolled in this trial had advanced disease

and had failed treatment with marketed therapies, a significant number of them

were particularly responsive to Syk inhibition with R788, " said

Friedberg, M.D., M.S.Sc., Associate Professor of Medicine, P. Wilmot

Cancer Center, University of Rochester and lead investigator for the clinical

trial. " I am encouraged by this data and look forward to conducting additional

trials of R788, particularly in patients with DLBCL and CLL/SLL types of

non-Hodgkin's lymphomas, " he added.

Full story

http://www.marketwatch.com/news/story/Phase-2-Results-Rigels-R788/story.aspx?gui\

d=%7B696DFEAC-A128-4FEC-A7CF-F6C5E1B6F47E%7D